Analyst Price Target is GBX 355
▲ +11.22% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Mediclinic International in the last 3 months. The average price target is GBX 355, with a high forecast of GBX 370 and a low forecast of GBX 340. The average price target represents a 11.22% upside from the last price of GBX 319.20.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Mediclinic International.
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 hospitals, 2 day case clinics, 3 outpatient clinics, and 110 theatres with approximately 1,893 inpatient beds in Switzerland; 52 hospitals, 10 day case clinics, 8 sub-acute hospitals, and 305 theatres in South Africa and Namibia with approximately 8,792 inpatient beds; and 7 hospitals, 2 day case clinics, 18 outpatient clinics, and 38 theatres with approximately 927 inpatient beds in the United Arab Emirates. The company also provides treasury, hospital equipment and procurement, emergency medical, management, food and catering, healthcare management, and debt collection and related services; manages healthcare staff; and owns and manages properties. In addition, it engages in intellectual property holding and medical store/procurement businesses. The company was founded in 1983 and is based in Stellenbosch, South Africa.